J. Bomalaski

发表

Argininosuccinate Synthetase 1 Loss in Invasive Bladder Cancer Regulates Survival through General Control Nonderepressible 2 Kinase-Mediated Eukaryotic Initiation Factor 2α Activity and Is Targetable by Pegylated Arginine Deiminase.

D. Hansel, G. Boss, A. Hau, 2017, The American journal of pathology.

Chapter 23 Response of the Endothelium to Tumor Necrosis Factor (Cachectin) and Interleukin-1

J. Bomalaski, M. A. Clark, P. Simon, 1987 .

Tumour necrosis factor (cachectin) induces phospholipase A2 activity and synthesis of a phospholipase A2-activating protein in endothelial cells.

S. Crooke, J. Bomalaski, M. A. Clark, 1988, The Biochemical journal.

Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties.

J. Bomalaski, M. A. Clark, C. Ensor, 2002, Journal of controlled release : official journal of the Controlled Release Society.

Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies.

J. Bomalaski, M. A. Clark, C. Ensor, 2002, The Journal of rheumatology.

Pegylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis

F. Izzo, S. Curley, G. Castello, 2007, Journal of gastroenterology and hepatology.

Phase III randomized study of second line ADI-peg 20 (A) plus best supportive care versus placebo (P) plus best supportive care in patients (pts) with advanced hepatocellular carcinoma (HCC).

F. Izzo, M. Colombo, Sheng-Nan Lu, 2016 .

Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma

F. Izzo, M. Colombo, Sheng-Nan Lu, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Phospholipase A2 and arthritis.

J. Bomalaski, M. A. Clark, 1993, Arthritis and rheumatism.

Responses of purified phospholipases A2 to phospholipase A2 activating protein (PLAP) and melittin.

J. Bomalaski, M. A. Clark, M. Steiner, 1993, Biochimica et biophysica acta.

Aspirin inhibits phospholipase C.

F. Hirata, J. Bomalaski, M. A. Clark, 1986, Biochemical and biophysical research communications.

Monosodium urate crystals in the knee joints of patients with asymptomatic nontophaceous gout.

H. Schumacher, J. Bomalaski, G. Lluberas, 1986, Arthritis and rheumatism.

Enhanced phospholipase activity in peripheral blood monocytes from patients with rheumatoid arthritis.

J. Bomalaski, M. A. Clark, R. Zurier, 1986, Arthritis and rheumatism.

Enhanced Phospholipase A2 and C Activities of Peripheral Blood Polymorphonuclear Leukocytes From Patients With Rheumatoid Arthritis

J. Bomalaski, M. A. Clark, S. Douglas, 1985, Journal of leukocyte biology.

Thrombocytopenia in a prospective, randomized, double-blind trial of bovine and porcine heparin.

G. Martin, J. Bomalaski, D. Green, 1984, The American journal of the medical sciences.

Evaluation of Arginine Deiminase Treatment in Melanoma Xenografts Using 18F-FLT PET

Valerie A Longo, S. Larson, I. Sauer, 2013, Molecular Imaging and Biology.

A Phase 1 study of ADI‐PEG20 (pegargiminase) combined with cisplatin and pemetrexed in ASS1‐negative metastatic uveal melanoma

P. Szlosarek, J. Bomalaski, M. Sheaff, 2022, Pigment cell & melanoma research.

Novel Mechanistic Insights into Arginine Deiminase Pharmacology Suggest 18F-FDG Is Not Suitable to Evaluate Clinical Response in Melanoma

S. Larson, L. Old, A. Jungbluth, 2012, The Journal of Nuclear Medicine.

Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase

M. Wangpaichitr, N. Savaraj, Chunjing Wu, 2012, British Journal of Cancer.

Incidence and distribution of argininosuccinate synthetase deficiency in human cancers

S. Curley, V. Prieto, J. Bomalaski, 2004, Cancer.

Concomitant activation of extracellular signal-regulated kinase and induction of COX-2 stimulates maximum prostaglandin E2 synthesis in human airway epithelial cells.

P. Thompson, N. Misso, D. Knight, 2006, Prostaglandins & other lipid mediators.

Regulation of synovial cell growth: basic fibroblast growth factor synergizes with interleukin 1 beta stimulating phospholipase A2 enzyme activity, phospholipase A2 activating protein production and release of prostaglandin E2 by rheumatoid arthritis synovial cells in culture.

J. Bomalaski, M. A. Clark, D. Goddard, 1992, Cytokine.

Phospholipase A2-mediated inflammation induces regression of malignant gliomas.

J. Bomalaski, M. A. Clark, S. Lipper, 1996, Cancer letters.

Phospholipase A2-activating protein induces the synthesis of IL-1 and TNF in human monocytes.

A. Hudson, J. Bomalaski, M. A. Clark, 1995, Journal of immunology.

Monosodium urate crystals stimulate phospholipase A2 enzyme activities and the synthesis of a phospholipase A2-activating protein.

J. Bomalaski, M. A. Clark, D. Baker, 1990, Journal of immunology.

Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers

Jianjun Gao, J. Blando, P. Szlosarek, 2021, Oncoimmunology.

Role of 3'-Deoxy-3'-[18F] Fluorothymidine Positron Emission Tomography-Computed Tomography as a Predictive Biomarker in Argininosuccinate Synthetase 1-Deficient Thoracic Cancers Treated With Pegargiminase

V. Goh, P. Szlosarek, L. Pike, 2022, JTO clinical and research reports.

A phase 1/1B trial of ADI‐PEG 20 plus nab‐paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma

G. Abou-Alfa, J. Harding, M. Lowery, 2017, Cancer.

Alcohol, immunosuppression, and the lung.

J. Phair, J. Bomalaski, John P. Phair, 1982, Archives of internal medicine.

Analysis of peritoneal macrophages in continuous ambulatory peritoneal dialysis patients.

E. Neilson, J. Bomalaski, S. Douglas, 1984, Kidney international.

Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma

J. Wolchok, J. Erinjeri, A. Shoushtari, 2022, Cancers.

Phase I study of ADI‐PEG20 plus low‐dose cytarabine for the treatment of acute myeloid leukemia

J. Bomalaski, H. Hsiao, Tsai-Yun Chen, 2021, Cancer medicine.

The role of phospholipase A2 activating protein (PLAP) in regulating prostanoid production in smooth muscle and endothelial cells following leukotriene D4 treatment.

S. Crooke, J. Bomalaski, M. A. Clark, 1990, Advances in experimental medicine and biology.

Abstract 3652: Pegylated arginine deiminase (ADI-PEG20) as a potential therapeutic agent for rarer variants of bladder cancer that are deficient for argininosuccinate synthetase

D. Hansel, Sounak Gupta, J. Bomalaski, 2012 .

Uptake of fatty acids and their mobilization from phospholipids in cultured monocyte-macrophages from rheumatoid arthritis patients.

J. Bomalaski, S. Douglas, A. Dailey, 1986, Clinical immunology and immunopathology.

Alteration of uptake and distribution of eicosanoid precursor fatty acids by aspirin.

J. Bomalaski, R. Zurier, J. Touchstone, 1987, Biochemical pharmacology.

Differential effects of aspirin and dexamethasone on phospholipase A2 and C activities and arachidonic acid release from endothelial cells in response to bradykinin and leukotriene D4.

S. Crooke, J. Bomalaski, M. A. Clark, 1986, Prostaglandins.

Regulation of fibroblast proliferation and collagen synthesis by cytokines.

S. Jimenez, J. Bomalaski, B. Freundlich, 1986, Immunology today.

Human extracellular recombinant phospholipase A2 induces an inflammatory response in rabbit joints.

P. Lawton, J. Browning, J. Bomalaski, 1991, Journal of immunology.

Binding of leukotriene B4 and its analogs to human polymorphonuclear leukocyte membrane receptors.

J. Bomalaski, S. Mong, S. Mong, 1987, Prostaglandins.

Inferior vena cava interruption in the management of pulmonary embolism.

G. Martin, J. Bomalaski, R. Hughes, 1982, Chest.

Leukotriene B4 Modulates Phospholipid Methylation and Chemotaxis in Human Polymorphonuclear Leukocytes

J. Bomalaski, M. A. Clark, L. Brophy, 1990, Journal of leukocyte biology.

Activation of phospholipase A2 in rheumatoid arthritis.

J. Bomalaski, M. A. Clark, 1990, Advances in experimental medicine and biology.

Yeast mitochondria (Saccharomyces cerevisiae) contain Ca(2+)-independent phospholipase A1 and A2 activities: effect of respiratory state.

R. W. Yost, A. Hudson, J. Bomalaski, 1991, Biochemistry international.

Separation of Prostaglandins E1, and E2 and other Major Eicosanoids by Unidimensional Argentation Thin Layer Chromatography

J. Bomalaski, A. Dailey, R. Zurier, 1984 .

Phase I/II trial of pegylated arginine deiminase (ADI-PEG20) in unresectable hepatocellular carcinoma

S. Curley, K. Delman, M. Thomas, 2005 .

Activation of mechanonociceptors by pro-inflammatory peptides melittin and PLAP peptide

J. Bomalaski, B. Cooper, 2004, Experimental Brain Research.

Phase II trial of pegylated arginine deiminase in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma.

G. Schwartz, K. Ganjoo, B. V. Van Tine, 2021 .

Infectious arthritis in renal transplant patients.

J. Bomalaski, C. S. Goldstein, P. K. Williamson, 1986, Arthritis and rheumatism.

A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma

T. Crook, P. Szlosarek, R. Jena, 2019, Clinical Cancer Research.

Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo.

J. Bomalaski, M. A. Clark, Charles Mark Ensor, 2002, Cancer research.

Oculocutaneous albinism, platelet storage pool disease, and progressive lupus nephritis.

J. Bomalaski, F. Carone, D. Green, 1983, Archives of internal medicine.

A phospholipase A2-activating protein (PLAP) stimulates human neutrophil aggregation and release of lysosomal enzymes, superoxide, and eicosanoids.

J. Bomalaski, M. A. Clark, D. Baker, 1989, Journal of immunology.

Cyclic adenosine 3'5' monophosphate stimulates prostaglandin E production by human adherent synovial cells.

J. Bomalaski, D. Baker, R. Zurier, 1985, Prostaglandins.

Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies.

F. Izzo, P. Vallone, S. Curley, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Arginine Deprivation Inhibits the Warburg Effect and Upregulates Glutamine Anaplerosis and Serine Biosynthesis in ASS1-Deficient Cancers

Jason M. Held, B. V. Van Tine, G. Bean, 2017, Cell reports.

Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1–Deficient Thoracic Cancers

G. Cook, P. Szlosarek, J. Spicer, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1–Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial

S. Beck, J. Shamash, L. Butcher, 2017, JAMA oncology.

Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors

K. Kelly, D. Gandara, J. Bomalaski, 2015, Clinical Cancer Research.

Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin

M. Wangpaichitr, N. Savaraj, Chunjing Wu, 2015, Oncotarget.

Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma

T. Crook, P. Szlosarek, H. Coley, 2013, Cell Death and Disease.

Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma

J. Wolchok, P. Ott, A. Pavlick, 2013, Investigational New Drugs.

Phase 1, pharmacogenomic, dose‐expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1‐deficient non‐squamous non‐small cell lung cancer

P. Szlosarek, J. Bomalaski, M. Sheaff, 2021, Cancer medicine.

MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion

Nicholas T. Ingolia, Kristofer C. Berrett, R. Deberardinis, 2019, Clinical Cancer Research.

Serum uric acid-lowering therapies: Where are we heading in management of hyperuricemia and the potential role of uricase

Mike A. Clark, J. Bomalaski, M. A. Clark, 2004, Current rheumatology reports.

Phase II Study of Arginine Deprivation Therapy With Pegargiminase in Patients With Relapsed Sensitive or Refractory Small-cell Lung Cancer.

P. Szlosarek, L. Krug, J. Bomalaski, 2020, Clinical lung cancer.

A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients

W. Hung, S. Jiang, J. Cortes, 2017, Scientific Reports.

Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo.

J. Gribben, J. Cavenagh, P. Szlosarek, 2015, Blood.

Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1–Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms

J. Shamash, P. Szlosarek, J. Spicer, 2020, JTO clinical and research reports.

Identification and isolation of a phospholipase A2 activating protein in human rheumatoid arthritis synovial fluid: induction of eicosanoid synthesis and an inflammatory response in joints injected in vivo.

S. Crooke, J. Bomalaski, M. A. Clark, 1990, The Journal of laboratory and clinical medicine.

Inferior Vena Cava Interruption in the Management of

G. Martin, J. Bomalaski, R. Hughes, 2017 .

Phase 1 trial of ADI‐PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors

F. Meric-Bernstam, F. Janku, S. Piha-Paul, 2021, Cancer medicine.

Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single‐arm, phase 2 study

G. Abou-Alfa, J. Harding, C. Yen, 2021, Cancer.

TITLE: A Phase I study of pegylated arginine deiminase (pegargiminase), cisplatin and pemetrexed in argininosuccinate synthetase 1-deficient recurrent high-grade glioma

T. Crook, P. Szlosarek, R. Jena, 2019 .

Atypical chest pain with a systolic murmur.

G. Martin, J. Bomalaski, D. Mehlman, 1983, Archives of internal medicine.

Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging.

Yong-jie Lu, I. Tomlinson, B. Delage, 2014, Cancer Research.

Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies.

F. Izzo, P. Ascierto, E. Simeone, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Argininosuccinate synthetase (ASS) deficiency in high-grade pulmonary neuroendocrine carcinoma: an opportunity for personalized targeted therapy

S. Orsulic, J. Bomalaski, A. Walts, 2015, Journal of Cancer Research and Clinical Oncology.

Arginine Deprivation With Pegylated Arginine Deiminase Induces Death Of Acute Myeloid Leukaemia Cells In Vivo

J. Gribben, P. Szlosarek, J. Bomalaski, 2013 .

Using pegylated arginine deiminase (ADI-PEG20) for the treatment of sarcomas that lack argininosuccinate synthesase 1 expression.

B. Rubin, G. Bean, B. V. Tine, 2013 .

Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis

J. Gribben, J. Fitzgibbon, L. Maharaj, 2012, Cell Death and Disease.

Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase

L. Old, A. Jungbluth, J. Bomalaski, 2011, British Journal of Cancer.

Regression of hepatocellular cancer in a patient treated with arginine deiminase.

S. Curley, J. Bomalaski, M. A. Clark, 2003, Hepato-gastroenterology.

Exploiting Arginine Auxotrophy with Pegylated Arginine Deiminase (ADI-PEG20) to Sensitize Pancreatic Cancer to Radiotherapy via Metabolic Dysregulation

J. Bomalaski, S. Krishnan, A. Deorukhkar, 2019, Molecular Cancer Therapeutics.

Enzymic degradation of plasma arginine using arginine deiminase inhibits nitric oxide production and protects mice from the lethal effects of tumour necrosis factor α and endotoxin

J. B. Thomas, J. Bomalaski, M. A. Clark, 2002 .

Enzymic degradation of plasma arginine using arginine deiminase inhibits nitric oxide production and protects mice from the lethal effects of tumour necrosis factor alpha and endotoxin.

J. B. Thomas, J. Bomalaski, M. A. Clark, 2002, The Biochemical journal.

A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies

G. Abou-Alfa, J. Harding, Chien-Feng Li, 2018, Cancer Chemotherapy and Pharmacology.

Phase 1 study of pegargiminase combined with cisplatin and pemetrexed in patients with ASS1-deficient uveal melanoma.

P. Szlosarek, J. Bomalaski, M. Sheaff, 2018 .

Differential expression of argininosuccinate synthetase in serous and non‐serous ovarian carcinomas

B. Karlan, S. Orsulic, J. Bomalaski, 2014, The journal of pathology. Clinical research.

Clinical assessment of the 1987 American College of Rheumatology criteria for rheumatoid arthritis.

H. Schumacher, J. Bomalaski, D. Baker, 1996, Scandinavian journal of rheumatology.

Imaging of tumor vascularization using fluorescence molecular tomography to monitor arginine deiminase treatment in melanoma.

Valerie A Longo, S. Larson, L. Old, 2013, Molecular imaging.

Biochemical characterization of the arginine degrading enzymes arginase and arginine deiminase and their effect on nitric oxide production.

J. Bomalaski, M. A. Clark, C. Ensor, 2002, Medical science monitor : international medical journal of experimental and clinical research.

Arginine deprivation alters microglial polarity and synergizes with radiation to eradicate non-arginine-auxotrophic glioblastoma tumors

K. Shah, T. Crook, N. Syed, 2022, The Journal of clinical investigation.

Salicylate-induced rhabdomyolysis.

J. Bomalaski, L. Leventhal, L. Kuritsky, 1989, The American journal of emergency medicine.

The chief medical residency in the 1980s.

G. Martin, J. Bomalaski, 1983, The American journal of medicine.

Cholera toxin induces synthesis of phospholipase A2-activating protein

S. Saini, J. Peterson, J. Bomalaski, 1996, Infection and immunity.

The effect of sn-2 fatty acid substitution on phospholipase C enzyme activities.

J. Bomalaski, M. A. Clark, 1987, Biochemical Journal.

Antibodies prepared to Bacillus cereus phospholipase C crossreact with a phosphatidylcholine preferring phospholipase C in mammalian cells.

J. Bomalaski, M. A. Clark, R. Shorr, 1986, Biochemical and biophysical research communications.

The Role of Fatty Acid Metabolites in the Differentiation of the Human Monocyte‐Like Cell Line U937

J. Bomalaski, M. A. Clark, B. Freundlich, 1988, Journal of leukocyte biology.

Efficacy of arginine depletion by ADI-PEG20 in an intracranial model of GBM

E. Want, T. Crook, P. Szlosarek, 2018, Cell Death & Disease.

General internal medicine consultation. The last bridge.

G. Martin, J. Bomalaski, J. Webster, 1983, Archives of internal medicine.

A metabolic synthetic lethal strategy with arginine deprivation and chloroquine leads to cell death in ASS1-deficient sarcomas

B. V. Van Tine, B. Rubin, G. Bean, 2016, Cell Death and Disease.

Granulocyte functions are independent of arginine availability

T. Giese, J. Bomalaski, I. Müller, 2014, Journal of leukocyte biology.

Cloning of a phospholipase A2-activating protein.

S. Crooke, J. Bomalaski, M. A. Clark, 1991, Proceedings of the National Academy of Sciences of the United States of America.

IL-1 increases phospholipase A2 activity, expression of phospholipase A2-activating protein, and release of linoleic acid from the murine T helper cell line EL-4.

J. Bomalaski, M. A. Clark, P. Simon, 1992, Journal of immunology.

A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma

P. Szlosarek, F. Balkwill, C. Chelala, 2023, Pharmacological Reports.

Argininosuccinate Synthetase-1 (ASS1) Loss in High-Grade Neuroendocrine Carcinomas of the Urinary Bladder: Implications for Targeted Therapy with ADI-PEG 20

J. Cheville, S. Boorjian, I. Frank, 2018, Endocrine Pathology.

ATOMIC-Meso: A randomized phase 2/3 trial of ADI-PEG20 or placebo with pemetrexed and cisplatin in patients with argininosuccinate synthetase 1-deficient non-epithelioid mesothelioma.

M. Zauderer, A. Mansfield, G. Ceresoli, 2017 .

Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies

S. Patel, F. Janku, A. Naing, 2021, British Journal of Cancer.

Phase II study of pegylated arginine deiminase (ADI-PEG20), a novel targeted therapy for melanoma.

N. Savaraj, L. Feun, J. Bomalaski, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pegylated arginine deiminase drives arginine turnover and systemic autophagy to dictate energy metabolism

B. V. Van Tine, J. Bomalaski, Yiming Zhang, 2022, Cell reports. Medicine.

Podagra is more than gout.

H. Schumacher, J. Bomalaski, 1984, Bulletin on the rheumatic diseases.

Prostaglandins and the inflammatory response.

J. Bomalaski, R. Zurier, P. K. Williamson, 1983, Clinics in laboratory medicine.

Efficacy of arginine depletion by ADI-PEG20 in an intracranial model of GBM

E. Want, T. Crook, P. Szlosarek, 2018, Cell Death & Disease.

The Purification of Two Intracellular Phospholipase A2s and the Effects of Phospholipase A2 Activating Protein and Mellitin on Their Activities

J. Bomalaski, M. A. Clark, M. Steiner, 1991 .

Phospholipase A2 activity in human neutrophils. Stimulation by lipopolysaccharide and possible involvement in priming for an enhanced respiratory burst.

J. Bomalaski, R. Johnston, J. Forehand, 1993, Journal of Immunology.

Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin

M. Wangpaichitr, N. Savaraj, Chunjing Wu, 2015, Oncotarget.

Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo.

J. Bomalaski, M. A. Clark, C. Ensor, 2002, Cancer Research.

D. Hansel, G. Boss, A. Hau, 2017, The American journal of pathology.

Rheumatoid arthritis synovial fluid phospholipase A2 activating protein (PLAP) stimulates human neutrophil degranulation and superoxide ion production

J. Bomalaski, M. A. Clark, D. Baker, 1989, Agents and Actions.

Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging.

I. Tomlinson, B. Delage, T. Crook, 2014, Cancer research.

Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo.

J. Bomalaski, M. A. Clark, C. Ensor, 2002, Cancer research.

Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial.

M. Zauderer, G. Ceresoli, P. Szlosarek, 2024, JAMA oncology.

New heart murmur and fever in a patient with systemic lupus erythematosus.

J. Bomalaski, J. Talano, S. Perlman, 1982, Archives of internal medicine.